First Known Opiate Biomarker Shows Fentanyl’s Effect on Brain

Fentanyl depresses breathing about 4 minutes before symptoms of distress are evident at a dose that is 1700 times lower than that needed for sedation, new research shows. This new information comes after researchers identified a unique EEG signature produced by fentanyl, the first known biomarker of an opiate’s effect on the brain. By monitoring … Read more

Toward a New Open-Door Model for Psychiatric Wards

If isolated, patients with mental disorders may end up having higher levels of social impairment. This has led several hospitals in Spain to set up open-door departments that are more accessible. The purpose of the open-door model is to help remove the stigma from individuals who need to be admitted to a psychiatric ward because … Read more

Ketamine Linked to Reduced Suicidal Thoughts, Depression, Anxiety

Ketamine infusions can help reduce symptoms of suicidal ideation, depression, and anxiety in patients with treatment-resistant depression (TRD), new research suggests. Results from a retrospective chart review analysis, which included more than 400 participants with TRD, illustrated that ketamine is a safe and rapid treatment in a real-world patient population, lead author Patrick A. Oliver, … Read more

Clozapine Best Choice for Reducing SUD Risk in Schizophrenia?

Clozapine or antipsychotic polytherapy appear to be the best approach in reducing the risk for a substance use disorder (SUD) in adults with schizophrenia and for preventing relapse in patients with both diagnoses, results of a real-world study show. “Our findings are in line with a recent meta-analysis showing superior efficacy of clozapine in schizophrenia … Read more

Borderline Personality Disorder Raises MDD Relapse Risk After ECT

Borderline personality disorder was significantly associated with relapse after 6 months in adults with major depressive disorder who underwent electroconvulsive therapy (ECT), based on data from 109 individuals. Dr Matthieu Hein ECT has demonstrated effectiveness for treatment of unipolar and bipolar major depression, but relapses within 6 months are frequent, and potential factors affecting relapse … Read more

CA Lawmakers Approve Mental Health Care Plan for Homeless

SACRAMENTO, Calif. (AP) — California will establish a new court program to steer — even force — homeless people with severe mental disorders into treatment after lawmakers on Wednesday gave final approval to a proposal pitched in March by Democratic Gov. Gavin Newsom. The Senate unanimously agreed to changes approved in the Assembly late Tuesday, … Read more

I Missed It: Coping With Medical Error

Thursday Night It was 9 o’clock at night when my phone rang. I didn’t recognize the number but decided to answer it anyway. It was my doctor. “Chase, I got your labs back and you have a critically low level. I spoke with someone at the hospital, I think I know what is happening, but … Read more

APA Report, Virtual Model Highlight US Psychiatric Bed Crisis

To address the ongoing shortage of available beds in psychiatric facilities, the American Psychiatric Association (APA) has developed a computer-simulation model to help estimate the number of beds needed in any specific US community. The model, introduced in a recent report from the organization, can predict how changes in any component of mental health care … Read more

Chemokine Expression Predicts MDD Severity

Adults with major depressive disorder (MDD) had significantly reduced expression of chemokine receptor 4 on blood T lymphocytes, which predicted disease severity in combination with polygenic risk scores in a study of 54 individuals. Chemokines and their receptors “influence neuroendocrine signaling, neurotransmission, and interaction between neurons and microglia and have therefore been suggested to be … Read more

LAIAs More Effective Than Oral Antipsychotics for Schizophrenia

For patients with schizophrenia, long-acting injectable antipsychotics (LAIAs) are associated with a lower risk than oral antipsychotics (OAs) for disease relapse and hospitalization ― and they carry no increased risk for adverse events, new research shows. Investigators analyzed data for more than 70,000 patients with schizophrenia and found that, compared with OAs, LAIAs were associated … Read more